J. Molner (MOLNR) H1 2025 earnings summary

Executive summary

• Strengthened position in the U.S. generic pharmaceutical market with the launch of Desoximetasone Ointment and new development agreements expanding the U.S. pipeline and eliminating future royalties on key products.

• Entered a new development agreement with a U.S. partner, leading to adjusted financial reporting due to prepayment accounting.

• Continued investment in internal capabilities to support future product launches and competitiveness.

Financial highlights

• Revenue for H1 2025 was €551,129, a 58% decrease year-over-year; adjusted revenue was €1,091,816.

• EBITDA was €(1,381,634), net loss €(1,411,802); adjusted EBITDA €(840,947), adjusted net loss €(871,115).

• Cash balance at June 30, 2025 was €207,292, down from €611,512 a year earlier.

• Operating cash flow was €(803,718), investing cash flow €(585,398), and financing cash flow €1,380,858.

Outlook and guidance

• Strategic focus on proprietary product development is expected to continue, with ongoing investments in team expansion and regulatory compliance.